TY - JOUR
T1 - Clonidine for sedation in infants during therapeutic hypothermia with neonatal encephalopathy
T2 - pilot study
AU - Gauda, Estelle B.
AU - Chavez-Valdez, Raul
AU - Northington, Frances J.
AU - Lee, Carlton K.K.
AU - Rudek, Michelle A.
AU - Guglieri-Lopez, Beatriz
AU - Ivaturi, Vijay
N1 - Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Nature America, Inc.
PY - 2022/3
Y1 - 2022/3
N2 - Objective: To determine a safe dose of clonidine (CLON) to be used in infants with hypoxic ischemic encephalopathy (HIE) undergoing therapeutic hypothermia (TH). Study design: A pilot prospective study was performed to determine the effect of CLON on autonomic parameters, the pharmacokinetics (PK) of CLON, and the amount of morphine (MOR) given “as needed” for shivering and agitation in a cohort of infants (n = 12) with HIE undergoing TH compared to a historical control group (n = 28). Results: The CLON group received less “as needed” MOR than the MOR-only group for agitation/shivering (p < 0.001), and the CLON vs. MOR-only group spent 92% vs. 79% of cooling time at the target core body temperature (CBT; p = 0.03, CLON vs. MOR). Conclusions: Intravenous CLON (1 mcg/kg Q8h) is well tolerated in infants treated with TH for HIE. CLON stabilizes CBT in the ideal range during cooling, which may be optimal for neuroprotection.
AB - Objective: To determine a safe dose of clonidine (CLON) to be used in infants with hypoxic ischemic encephalopathy (HIE) undergoing therapeutic hypothermia (TH). Study design: A pilot prospective study was performed to determine the effect of CLON on autonomic parameters, the pharmacokinetics (PK) of CLON, and the amount of morphine (MOR) given “as needed” for shivering and agitation in a cohort of infants (n = 12) with HIE undergoing TH compared to a historical control group (n = 28). Results: The CLON group received less “as needed” MOR than the MOR-only group for agitation/shivering (p < 0.001), and the CLON vs. MOR-only group spent 92% vs. 79% of cooling time at the target core body temperature (CBT; p = 0.03, CLON vs. MOR). Conclusions: Intravenous CLON (1 mcg/kg Q8h) is well tolerated in infants treated with TH for HIE. CLON stabilizes CBT in the ideal range during cooling, which may be optimal for neuroprotection.
UR - http://www.scopus.com/inward/record.url?scp=85115219517&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85115219517&partnerID=8YFLogxK
U2 - 10.1038/s41372-021-01151-1
DO - 10.1038/s41372-021-01151-1
M3 - Article
C2 - 34531532
AN - SCOPUS:85115219517
SN - 0743-8346
VL - 42
SP - 319
EP - 327
JO - Journal of Perinatology
JF - Journal of Perinatology
IS - 3
ER -